Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Herbicide-treated hay as a possible cause of dermatitis in horses.

Ross GD, Cranstoun KE.

Vet Rec. 2009 Feb 7;164(6):188. No abstract available.

PMID:
19202183
2.

Assays for membrane complement receptors.

O'Rear LD, Ross GD.

Curr Protoc Immunol. 2001 May;Chapter 13:Unit 13.4. doi: 10.1002/0471142735.im1304s10.

PMID:
18432717
3.

Isolation and purification of C3 from human plasma.

O'Rear LD, Ross GD.

Curr Protoc Immunol. 2001 May;Chapter 13:Unit 13.3. doi: 10.1002/0471142735.im1303s14.

PMID:
18432716
4.
5.

C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan.

Allendorf DJ, Yan J, Ross GD, Hansen RD, Baran JT, Subbarao K, Wang L, Haribabu B.

J Immunol. 2005 Jun 1;174(11):7050-6.

6.

Transplantation studies in C3-deficient animals reveal a novel role of the third complement component (C3) in engraftment of bone marrow cells.

Ratajczak MZ, Reca R, Wysoczynski M, Kucia M, Baran JT, Allendorf DJ, Ratajczak J, Ross GD.

Leukemia. 2004 Sep;18(9):1482-90.

PMID:
15284858
7.

Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models.

Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, Xing PX, Cheung NK, Ross GD.

J Immunol. 2004 Jul 15;173(2):797-806.

8.

Complement function in mAb-mediated cancer immunotherapy.

Gelderman KA, Tomlinson S, Ross GD, Gorter A.

Trends Immunol. 2004 Mar;25(3):158-64. Review. No abstract available.

PMID:
15036044
9.

Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.

Hong F, Hansen RD, Yan J, Allendorf DJ, Baran JT, Ostroff GR, Ross GD.

Cancer Res. 2003 Dec 15;63(24):9023-31.

10.

Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow.

Ratajczak J, Reca R, Kucia M, Majka M, Allendorf DJ, Baran JT, Janowska-Wieczorek A, Wetsel RA, Ross GD, Ratajczak MZ.

Blood. 2004 Mar 15;103(6):2071-8. Epub 2003 Nov 6.

PMID:
14604969
11.

Function of the lectin domain of Mac-1/complement receptor type 3 (CD11b/CD18) in regulating neutrophil adhesion.

Xia Y, Borland G, Huang J, Mizukami IF, Petty HR, Todd RF 3rd, Ross GD.

J Immunol. 2002 Dec 1;169(11):6417-26.

12.
13.
14.

Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan.

Yan J, Vetvicka V, Xia Y, Hanikýrová M, Mayadas TN, Ross GD.

Immunopharmacology. 2000 Jan;46(1):39-54.

PMID:
10665778
15.
16.

Therapeutic intervention with complement and beta-glucan in cancer.

Ross GD, Vetvicka V, Yan J, Xia Y, Vetvicková J.

Immunopharmacology. 1999 May;42(1-3):61-74. Review.

PMID:
10408367
19.

Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.

Vĕtvicka V, Hanikýrová M, Vĕtvicková J, Ross GD.

Clin Exp Immunol. 1999 Feb;115(2):229-35.

20.
21.
24.

Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18).

Thornton BP, Vĕtvicka V, Pitman M, Goldman RC, Ross GD.

J Immunol. 1996 Feb 1;156(3):1235-46.

PMID:
8558003
25.

Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes.

Thornton BP, Vĕtvicka V, Ross GD.

J Immunol. 1994 Feb 15;152(4):1727-37.

PMID:
8120381
26.

Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle.

Pemberton M, Anderson G, Vĕtvicka V, Justus DE, Ross GD.

J Immunol. 1993 Jun 1;150(11):5104-13.

PMID:
8496606
27.
28.

Complement factors H and I synthesized by B cell lines function to generate a growth factor activity from C3.

Vĕtvicka V, Reed W, Hoover ML, Ross GD.

J Immunol. 1993 May 1;150(9):4052-60.

PMID:
8473749
30.

Macrophage cytoskeleton association with CR3 and CR4 regulates receptor mobility and phagocytosis of iC3b-opsonized erythrocytes.

Ross GD, Reed W, Dalzell JG, Becker SE, Hogg N.

J Leukoc Biol. 1992 Feb;51(2):109-17.

PMID:
1358992
31.

Complement receptor type 1.

Ross GD.

Curr Top Microbiol Immunol. 1992;178:31-44. Review. No abstract available.

PMID:
1424775
32.

Staurosporine inhibits neutrophil phagocytosis but not iC3b binding mediated by CR3 (CD11b/CD18).

Roubey RA, Ross GD, Merrill JT, Walton F, Reed W, Winchester RJ, Buyon JP.

J Immunol. 1991 May 15;146(10):3557-62.

PMID:
1673986
33.
34.

Bibliography of complement research for 1989.

Ross GD.

Complement Inflamm. 1991;8(2):104-20. No abstract available.

PMID:
2055008
35.

Synthesis of complement component C5 by human B and T lymphoblastoid cell lines.

Reed W, Roubey RA, Dalzell JG, Matteucci BM, Myones BL, Hunt SW 3rd, Kolb WP, Ross GD.

Immunogenetics. 1990;31(3):145-51.

PMID:
1969382
36.

Complement and complement receptors.

Ross GD.

Curr Opin Immunol. 1989 Oct;2(1):50-62. Review. No abstract available.

PMID:
2692625
37.

Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR4) activity resembling CR3.

Myones BL, Dalzell JG, Hogg N, Ross GD.

J Clin Invest. 1988 Aug;82(2):640-51.

38.

Dissociation between increased surface expression of gp165/95 and homotypic neutrophil aggregation.

Buyon JP, Abramson SB, Philips MR, Slade SG, Ross GD, Weissmann G, Winchester RJ.

J Immunol. 1988 May 1;140(9):3156-60.

PMID:
3283242
39.

Effect of antigen site and complement receptor status on the rate of cleavage of C3c antigen from red cell bound C3b.

Currie MS, Rustagi PK, Wojcieszak R, Ziolkowski L, Ross GD, Logue GL.

Blood. 1988 Mar;71(3):786-90.

PMID:
3345346
41.
42.

Specificity of membrane complement receptor type three (CR3) for beta-glucans.

Ross GD, Cain JA, Myones BL, Newman SL, Lachmann PJ.

Complement. 1987;4(2):61-74.

PMID:
3040332
43.

The complement receptor type 2 and factor H receptors.

Myones BL, Ross GD.

Methods Enzymol. 1987;150:586-601. No abstract available.

PMID:
2963198
45.

Receptor deficiencies. Complement receptor type three.

Ross GD.

Prog Allergy. 1986;39:352-60. No abstract available.

PMID:
3550818
46.

gp140, a C3b-binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4).

Frade R, Myones BL, Barel M, Krikorian L, Charriaut C, Ross GD.

Eur J Immunol. 1985 Dec;15(12):1192-7.

PMID:
3878789
47.

Characterization of patients with an increased susceptibility to bacterial infections and a genetic deficiency of leukocyte membrane complement receptor type 3 and the related membrane antigen LFA-1.

Ross GD, Thompson RA, Walport MJ, Springer TA, Watson JV, Ward RH, Lida J, Newman SL, Harrison RA, Lachmann PJ.

Blood. 1985 Oct;66(4):882-90.

PMID:
3899217
48.

Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.

Ross GD, Yount WJ, Walport MJ, Winfield JB, Parker CJ, Fuller CR, Taylor RP, Myones BL, Lachmann PJ.

J Immunol. 1985 Sep;135(3):2005-14.

PMID:
4020137
49.

p150/95, Third member of the LFA-1/CR3 polypeptide family identified by anti-Leu M5 monoclonal antibody.

Lanier LL, Arnaout MA, Schwarting R, Warner NL, Ross GD.

Eur J Immunol. 1985 Jul;15(7):713-8.

PMID:
3924634

Supplemental Content

Support Center